Healthcare Press

Clinical Controversy: Standard Dose or Baby TAM for Breast Cancer Prevention?

  • 📰 Medscape
  • ⏱ Reading Time:
  • 44 sec. here
  • 20 min. at publisher
  • 📊 Quality Score:
  • News: 84%
  • Publisher: 55%

Breast Cancer News

Malignant Breast Neoplasm,Breast Carcinoma,Cancer

Experts debate whether women at high risk for BC should receive tamoxifen at standard 20 mg dose or can get similar preventive benefit, with fewer toxicities, from lower dose.

Should 5 mg of tamoxifen — known as"baby TAM" — or the usual 20 mg dose be standard of care for breast cancer prevention in high-risk women?

De Censi and colleagues found that baby TAM reduced the risk for invasive breast cancer by 52% and the risk for contralateral breast cancer by 75%.showed ongoing benefits associated with baby TAM vs placebo — a 42% reduction in breast cancer and a 64% drop in contralateral lesions. De Censi said he's surprised the baby TAM vs tamoxifen topic is still being debated."Baby TAM, in my opinion, is a new standard of care for endocrine prevention of breast cancer in high-risk ," and baby TAM over 3 years is enough, said De Censi during a debate on the topic at the 2024 European Society for Medical Oncology Breast Cancer Congress in Berlin.

The vast weight of evidence for tamoxifen prophylaxis, he added, is in trials involving tens of thousands of women, followed in some cases for 20 years, who received the 20 mg dose for 5 years.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Jason Leitch joins board of private surgery firmScotland's former national clinical director will advice Elanic Medical on clinical governance.
Source: bbchealth - 🏆 143. / 63 Read more »

Clinical Trial Of Ketamine Tablets Shows Promising Results For Treatment-Resistant DepressionAnuradha Varanasi is a freelance science writer. She writes on the intersection of health/medicine, racial disparities, and climate change. She earned an MA in Science Journalism from Columbia University in New York City.
Source: ForbesTech - 🏆 318. / 59 Read more »

First Lyme Disease Vaccine in 20 Years Begins Final Clinical Trial—What You Need to KnowA new vaccine to prevent Lyme disease in humans is entering the final phase of clinical trials, manufacturers Pfizer and Valneva announced last week.
Source: Health - 🏆 396. / 53 Read more »